Prostatic fluid concentrations of isoflavonoids in soy consumers are sufficient to inhibit growth of benign and malignant prostatic epithelial cells in vitro
- 21 December 2005
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 66 (5) , 557-566
- https://doi.org/10.1002/pros.20380
Abstract
BACKGROUND: The differential intestinal metabolism of the soy isoflavones is likely to influence the ability of soy to prevent prostate cancer. While daidzein, genistein, and equol have direct antiproliferative effects on prostatic epithelial cells in vitro, there are no such data for the isoflavone glycitein, or seven metabolites: O‐desmethylangolensin (ODMA), 6‐hydroxyODMA (6H‐ODMA), dihydrodaidzein (DHD), cis‐4‐hydroxyequol (C4HE), 3′‐hydroxydaidzein (3HD), 6‐hydroxydaidzein (6HD), and 8‐hydroxydaidzein (8HD). In the current study, the in vitro activities of these compounds were elucidated, and the active ranges of concentrations were compared to that found in Caucasian prostatic fluid (PF) and plasma samples.METHODS: The effects of isoflavonoids on cell growth, cell cycle distribution, and apoptosis (active Caspase 3) were examined on benign prostatic epithelial cells (PrEC), and the prostate cancer cell line LNCaP.RESULTS: PF concentrations of genistein, equol, and daidzein (but not ODMA or DHD) were often within the ranges that reduce PrEC growth in vitro. Profound differences in sensitivities were observed with LNCaP. The hydroxydaidzeins, C4HE, and 6H‐ODMA had significant inhibitory effects at 10−5M on PrEC growth (but not LNCaP). Glycitein had significant effects on both. Reductions in cell growth were typically associated with both changes in cell cycle distribution and Caspase 3 activation. When five isoflavonoids were used in combination at concentrations present in PF samples, synergistic effects were observed.CONCLUSION: The profound differences in sensitivities of prostatic epithelial cells to these compounds along with their synergistic effects suggest that multiple metabolites in vivo may be optimal for preventing prostate cancer. ProstateKeywords
This publication has 27 references indexed in Scilit:
- Soy isoflavonoid equol modulates the growth of benign and malignant prostatic epithelial cells in vitroThe Prostate, 2002
- Role of stroma in carcinogenesis of the prostateDifferentiation, 2002
- Widely used prostate carcinoma cell lines share common originsThe Prostate, 2001
- Inhibition of 5α-reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoidsJournal of Endocrinology, 1995
- A serum‐free defined medium capable of supporting growth of four established human prostatic carcinoma cell linesThe Prostate, 1994
- Metabolites of dietary (soya) isoflavones in human urineClinica Chimica Acta; International Journal of Clinical Chemistry, 1993
- Plasma concentrations of phyto-oestrogens in Japanese menThe Lancet, 1993
- Inhibition of human aromatase by mammalian lignans and isoflavonoid phytoestrogensThe Journal of Steroid Biochemistry and Molecular Biology, 1993
- Effect of dietary components, including lignans and phytoestrogens, on enterohepatic circulation and liver metabolism of estrogens and on sex hormone binding globulin (SHBG)Journal of Steroid Biochemistry, 1987